

Title (en)

INTERLEUKIN-6 (IL-6) ANTAGONISTS

Title (de)

INTERLEUKIN-6 (IL-6) ANTAGONISTEN

Title (fr)

ANTAGONISTES D'INTERLEUKINE-6 (IL-6)

Publication

EP 0742794 A1 19961120 (EN)

Application

EP 95940401 A 19951205

Priority

- IT 9500208 W 19951205
- IT RM940794 A 19941206

Abstract (en)

[origin: WO9617869A2] These are antagonists of interleukin-6, characterised in that they consist of soluble forms of the receptor alpha of human IL-6 (shIL-6R alpha) containing one or more mutation in the gp130 binding interface. In a preferred embodiment, the mutations are present in a position chosen from the group comprising Ala 228, Asn 230, His 280 and Asp 281. These antagonists can be used as agents capable of preventing and treating diseases caused by abnormal IL-6 activity. The figure shows the antagonist activity of the mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val in comparison with the agonist properties of wild type shIL-6R alpha . This antagonist can be used for preparation of drugs for the prevention, control and treatment of diseases caused by abnormal IL-6 bioactivity.

IPC 1-7

C07K 14/715

IPC 8 full level

A61K 38/00 (2006.01); **C12N 15/09** (2006.01); **A61K 48/00** (2006.01); **A61P 37/00** (2006.01); **C07K 7/08** (2006.01); **C07K 14/715** (2006.01); **C12P 21/02** (2006.01); **C12R 1/91** (2006.01)

CPC (source: EP)

A61P 37/00 (2018.01); **C07K 14/7155** (2013.01); **A61K 38/00** (2013.01)

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9617869 A2 19960613; WO 9617869 A3 19960829; AU 4186696 A 19960626; CA 2177837 A1 19960607; CN 1139933 A 19970108; EP 0742794 A1 19961120; IT 1274350 B 19970717; IT RM940794 A0 19941206; IT RM940794 A1 19960606; JP H09503232 A 19970331

DOCDB simple family (application)

IT 9500208 W 19951205; AU 4186696 A 19951205; CA 2177837 A 19951205; CN 95191457 A 19951205; EP 95940401 A 19951205; IT RM940794 A 19941206; JP 51746696 A 19951205